Management of COPD

Goals of Therapy

1. Symptomatic relief - reduce respiratory symptoms, improve exercise tolerance and health status
2. Reduce future risk - prevent disease progression, prevent/treat exacerbations, reduce mortality

Non-Pharmacologic Interventions

• Pulmonary rehabilitation: Strongly recommended for patients with substantial limitation in daily activities. Post-hospitalization enrollment reduces mortality. Programs include exercise training, education, nutritional counseling, and psychological support.
• Exercise: Minimum 20-30 min of low-intensity aerobic activity (e.g., walking) at least 3x/week recommended for all patients. Rolling walkers help patients with hyperinflation.
• Nutritional support: 25-40% of COPD patients have nutritional depletion. Weight gain is associated with improved survival. Monitor BMI; encourage supplementation in underweight patients.
• Vaccinations: Influenza and pneumococcal vaccines are recommended.
• NIV (noninvasive positive-pressure ventilation): Indicated for severe chronic hypercapnia (PaCO2 >45 mmHg, pH ≤7.35).

Pharmacotherapy - Stable COPD

Step 1: Smoking Cessation Pharmacotherapy (for active smokers)

• Nicotine replacement therapy (gum, patch, lozenge, inhaler, nasal spray)
• Bupropion
• Varenicline (nicotinic receptor partial agonist) - most effective agent
• All adult, non-pregnant smokers should be offered pharmacotherapy + counseling

Step 2: Bronchodilators (cornerstone of COPD treatment)

Short-Acting Agents (for acute/as-needed relief)

Long-Acting Agents (for persistent symptoms / regular use)

• Tiotropium, aclidinium, umeclidinium, glycopyrrolate/glycopyrronium, revefenacin
• Tiotropium reduces exacerbations by 20-25% and reduces hospitalizations
• Duration: aclidinium ≥12h; tiotropium, umeclidinium, revefenacin >24h
• Side effects: dry mouth, urinary retention (main); avoid aerosolization near eyes (glaucoma risk)

• Arformoterol, formoterol, indacaterol, olodaterol, salmeterol, vilanterol
• Side effects: tremor, tachycardia

Step 3: Inhaled Corticosteroids (ICS)

• Severe airflow obstruction (FEV1 <50% predicted)
• History of frequent exacerbations despite dual bronchodilator therapy
• High blood eosinophil count (≥300 cells/μL = reasonable benefit predicted; <100 cells/μL = unlikely to benefit)
• Concurrent asthma-COPD overlap

Step 4: Triple Therapy (LABA + LAMA + ICS)

• Reduce exacerbations
• Reduce all-cause mortality in selected patients
• Reduce hospitalizations

Additional Pharmacologic Options

Phosphodiesterase-4 (PDE-4) Inhibitors

• Roflumilast (oral, selective PDE-4 inhibitor)
• Improves pulmonary function and reduces exacerbation frequency
• Approved for COPD with chronic bronchitis phenotype and frequent exacerbations
• Major side effects: weight loss, nausea, diarrhea, depression (monitor carefully)

Methylxanthines

• Theophylline - modest bronchodilator, some anti-inflammatory effects, improves inspiratory muscle function
• Not first-line - narrow therapeutic index, many drug interactions
• Target serum levels: 5-10 μg/mL (lower than historical 15-20 μg/mL)
• Reserve for patients intolerant of LABAs/LAMAs or where cost is prohibitive
• Recent RCT of low-dose theophylline showed no benefit on exacerbation frequency

Azithromycin (prophylactic)

• Long-term low-dose azithromycin reduces exacerbation frequency in selected high-risk patients
• Risk of hearing loss and cardiac arrhythmias must be considered

Opiates

• Short-acting, low-dose opiates can relieve severe dyspnea refractory to other therapy
• Typically reserved for end-stage/hospice management, but can be considered in less severe disease with refractory dyspnea

COPD Exacerbation Management (AECOPD)

Outpatient/Mild Exacerbations

• Increase frequency of short-acting bronchodilators (SABA ± SAMA, or nebulized)
• Short course of systemic corticosteroids
• Antibiotics if purulent sputum or clinical indication

Hospital Management

Prognostic Indices

• Body mass index
• Obstructive severity (FEV1 % predicted)
• Dyspnea (mMRC score)
• Exercise capacity (6-minute walk distance)

Recent Evidence (2024-2026)

• A 2025 systematic review and network meta-analysis (PMID: 39877958) assessed biologic therapies (dupilumab, mepolizumab, benralizumab) in COPD - an emerging area particularly for eosinophilic COPD phenotypes.
• A 2025 meta-analysis (PMID: 40420531) confirmed that higher-dose ICS in COPD is associated with increased risk of osteoporosis and fractures, reinforcing the eosinophil-guided, lowest-effective-dose approach.
• A 2025 meta-analysis from the EXACOS/AVOIDEX programme (PMID: 40707144) showed that COPD exacerbations significantly predict future exacerbations and mortality, underscoring the importance of exacerbation prevention as a treatment target.

Physiotherapy Management of COPD

"A comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote long-term adherence to health-enhancing behaviors."

Indications for Referral

1. Severe dyspnea and/or fatigue
2. Decreased exercise tolerance or low physical activity
3. Difficulty with activities of daily living (ADLs)
4. Impaired health-related quality of life
5. Frequent hospitalizations or emergency visits
6. Difficulty coping with / managing disease
7. Recovery from a COPD exacerbation (post-hospitalization - strongly recommended)
8. Preparation for or recovery from lung transplantation or lung surgery

Pre-Program Assessment

• Spirometry / Lung function testing - characterize disease severity (FEV1, FVC, lung volumes, diffusing capacity)
• Exercise testing - assess exercise tolerance, detect exercise-induced hypoxemia, uncover cardiac comorbidities, and establish a safe training prescription
  • Formal cardiopulmonary exercise test (CPET): incremental or steady-state protocols
  • 6-Minute Walk Test (6MWT) - practical, widely used; measures maximum walking distance; used for outcome tracking
• Arterial blood gas / pulse oximetry - identify resting or exertional hypoxemia (prescribe supplemental O2 if SpO2 falls)
• Symptom scales: mMRC Dyspnea Scale, COPD Assessment Test (CAT)
• Psychosocial assessment: anxiety, depression, self-efficacy

Core Components of Pulmonary Rehabilitation

1. Exercise Training (Cornerstone)

A. Aerobic / Endurance Training

• Modalities: Walking (treadmill), cycling (stationary bike)
• Target: Sustained exercise at 60-80% of peak work rate for 20-45 min, 3-5 times/week
• Improves exercise capacity, reduces dyspnea, and improves quality of life
• Both upper and lower extremity training recommended

B. Interval Training

• Alternating periods of high-intensity exercise and rest/low-intensity exercise
• Indicated for patients who cannot tolerate continuous endurance training due to severely impaired exercise capacity or severe dyspnea
• Achieves similar physiological benefits with reduced symptomatic burden during training

C. Resistance / Strength Training

• Free weights, resistance bands, weight machines
• Targets peripheral muscle weakness - especially quadriceps, which is strongly associated with mortality in COPD
• Complements aerobic training; particularly important in patients with significant sarcopenia

D. Upper Limb Training

• Upper extremity muscles serve dual roles (respiration + movement); targeted training reduces dyspnea during arm activities
• Includes both supported (arm ergometer) and unsupported arm exercises

E. Balance Training

• Increasingly recognized - COPD patients have increased fall risk
• Incorporated into comprehensive programs

F. Adjunct / Novel Modalities

• Whole-body vibration training - emerging evidence, useful in severely deconditioned patients
• Neuromuscular electrical stimulation (NMES) - for patients too breathless to exercise actively (e.g., during acute hospitalization)
• Yoga / Tai Chi - beneficial for breathlessness, balance, and psychological well-being

2. Breathing Retraining Techniques

A. Pursed-Lip Breathing (PLB)

• Patient tenses lips and narrows mouth opening during expiration
• Creates back-pressure to "stent airways open" and prevent dynamic collapse during expiration
• Slows respiratory rate, increases tidal volume, reduces air trapping
• Naturally adopted by many COPD patients; taught consciously in PR
• Consistently improves dyspnea; also reduces the oxygen cost of breathing in some patients

B. Diaphragmatic Breathing

• Patient consciously coordinates abdominal wall expansion with inspiration + slows expiration through pursed lips
• Primary effects: slows respiratory rate, increases tidal volume
• Improves respiratory muscle synchrony between abdominal and thoracic compartments
• Note: evidence for measurable physiologic improvement (vs. symptom relief) is less consistent

C. Forward-Leaning Posture

• Leaning forward with arms supported on a table or rollator walker
• Improves mechanical advantage of the diaphragm and accessory muscles
• Practically useful during exertional dyspnea

D. Pacing and Energy Conservation Techniques

• Activity planning, rest breaks, prioritizing tasks
• Reduces overall ventilatory demand and dyspnea during ADLs

3. Inspiratory Muscle Training (IMT)

• Uses threshold loading or flow resistive devices to strengthen inspiratory muscles
• Beneficial when respiratory muscle weakness is a significant contributor to dyspnea and exercise limitation
• Improves inspiratory muscle strength, reduces dyspnea
• Can be combined with general exercise training or used alone in patients unable to participate in whole-body exercise

4. Airway Clearance / Bronchial Hygiene Techniques

5. Psychosocial and Behavioral Support

• Cognitive-behavioral therapy (CBT) - addresses maladaptive fear of dyspnea, activity avoidance
• Relaxation techniques and biofeedback
• Stress management and coping skills training
• Group support - peer interaction is a valued component; improves motivation and adherence
• Self-management education: recognizing and managing exacerbations, inhaler technique, oxygen use, action plans

6. Patient Education

• Anatomy and physiology of COPD
• Benefits of exercise and physical activity
• Proper use of medications (including inhaler technique, timing)
• Benefits and practical use of supplemental oxygen and NIV
• Anxiety management, coping, and relaxation strategies
• Recognition and management of exacerbations (triggers, action plans)
• Pacing, energy conservation, and body positioning for dyspnea
• Nutrition
• Advance care planning / end-of-life discussions

• Smoking cessation
• Airway clearance techniques and infection prevention
• Pre- or post-transplant / lung surgery preparation

7. Nutritional Support

• 20-35% of stable COPD patients have low BMI, associated with:
  • Reduced respiratory and peripheral muscle strength
  • Lower exercise tolerance
  • Increased mortality
• Weight gain in depleted patients predicts improved survival
• Focus: nutritional supplementation combined with resistance training to build fat-free mass
• Monitor for both underweight and obesity (though COPD paradoxically has lower mortality in obese patients)

Outcomes of Pulmonary Rehabilitation

Program Delivery Models

• Centre-based PR: Traditional model; multidisciplinary team; most evidence-based; 6-12 weeks minimum, 2-3 supervised sessions/week
• Home-based PR: Equivalent outcomes to centre-based in stable COPD per 2024 meta-analysis (PMID: 39187265); improves access
• Post-exacerbation PR: Enrollment within 4 weeks of hospitalization reduces readmissions and mortality - strongly recommended (PMID: 38350731)
• Digital / telehealth PR: Growing evidence base; 2024 systematic review (PMID: 38929580) shows positive effects on exercise capacity and dyspnea; improves access in remote or mobility-limited patients
• Virtual reality-based PR: Emerging; 2023 meta-analysis (PMID: 37622840) shows benefits in exercise adherence and patient experience

PR in Special Contexts

• Pre-transplant: Maintains functional capacity through the waiting period; improves post-surgical outcomes
• Post-transplant: Rebuilds exercise capacity and manages new physical limitations
• LVRS preparation: PR is required pre-operatively to optimize candidacy and outcomes
• Severe/very severe COPD: PR is effective even with very severely impaired lung function, including those on LTOT